Diagnostic molecular biomarkers for malignant pleural effusions

Sriram, Krishna B., Relan, Vandana, Clarke, Belinda E., Duhig, Edwina E., Yang, Ian A., Bowman, Rayleen V., Lee, Y.C. Gary and Fong, Kwun M. (2011) Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncology, 7 6: 737-752. doi:10.2217/FON.11.45


Author Sriram, Krishna B.
Relan, Vandana
Clarke, Belinda E.
Duhig, Edwina E.
Yang, Ian A.
Bowman, Rayleen V.
Lee, Y.C. Gary
Fong, Kwun M.
Title Diagnostic molecular biomarkers for malignant pleural effusions
Journal name Future Oncology   Check publisher's open access policy
ISSN 1479-6694
Publication date 2011-06-01
Year available 2012
Sub-type Critical review of research, literature review, critical commentary
DOI 10.2217/FON.11.45
Open Access Status Not yet assessed
Volume 7
Issue 6
Start page 737
End page 752
Total pages 16
Place of publication London, England, U.K.
Publisher Future Medicine Ltd.
Language eng
Abstract Malignant pleural effusions (MPEs) are a common and important cause of cancer-related mortality and morbidity. Prompt diagnosis using minimally invasive tests is important because the median survival after diagnosis is only 4-9 months. Pleural fluid cytology is pivotal to current MPE diagnostic algorithms but has limited sensitivity (30-60%). Consequently, many patients need to undergo invasive diagnostic tests such as thoracoscopic pleural biopsy. Recent genomic, transcriptomic, methylation and proteomic studies on cells within pleural effusions have identified novel molecular diagnostic biomarkers that demonstrate potential in complementing cytology in the diagnosis of MPEs. Several challenges will need to be addressed prior to the incorporation of these molecular tests into routine clinical diagnosis, including validation of molecular diagnostic markers in well-designed prospective, comparative and cost-effectiveness studies. Ultimately, minimally invasive diagnostic tests that can be performed quickly will enable clinicians to provide the most effective therapies for patients with MPEs in a timely fashion.
Formatted abstract
Malignant pleural effusions (MPEs) are a common and important cause of cancer-related mortality and morbidity. Prompt diagnosis using minimally invasive tests is important because the median survival after diagnosis is only 4-9 months. Pleural fluid cytology is pivotal to current MPE diagnostic algorithms but has limited sensitivity (30-60%). Consequently, many patients need to undergo invasive diagnostic tests such as thoracoscopic pleural biopsy. Recent genomic, transcriptomic, methylation and proteomic studies on cells within pleural effusions have identified novel molecular diagnostic biomarkers that demonstrate potential in complementing cytology in the diagnosis of MPEs. Several challenges will need to be addressed prior to the incorporation of these molecular tests into routine clinical diagnosis, including validation of molecular diagnostic markers in well-designed prospective, comparative and cost-effectiveness studies. Ultimately, minimally invasive diagnostic tests that can be performed quickly will enable clinicians to provide the most effective therapies for patients with MPEs in a timely fashion. © 2011 Future Medicine Ltd.
Keyword Oncology
Respiratory System
Oncology
Respiratory System
ONCOLOGY
RESPIRATORY SYSTEM
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2012 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 40 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 41 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 14 Aug 2011, 11:00:20 EST by System User on behalf of School of Medicine